N/A
N=157
Defective Atypical Protein Kinase C (PKC) Activation in Diabetes and Metabolic Syndrome
Diabetes Mellitus, Type 2
Bottom Line
View on ClinicalTrials.gov: NCT00690755 ↗Enrolled (actual)
157
Serious AEs
0.0%
Results posted
May 2016
Primary outcome: Primary: Alterations in PKC-zeta mRNA in Vastus Lateralis Skeletal Muscles — 1.76; 3.58; 2.14; 2.22 arbitrary units/ng rRNA — p=.001
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- —
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- VA Office of Research and Development
- Primary completion
- Sep 2012
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Alterations in PKC-zeta mRNA in Vastus Lateralis Skeletal Muscles |
1.76; 3.58; 2.14; 2.22 | .001 sig |
Summary
The investigators are examining the activation of insulin signaling factors in skeletal muscles of human diabetics. The investigators are characterizing the defects in signaling, and are examining the effects of anti-diabetic agents and exercise on signaling to glucose transport biochemical machinery and whole body glucose disposal.
Eligibility Criteria
Inclusion Criteria
- Stable uncomplicated type 2 diabetes
- Able to be off oral treatments for 2 months
Exclusion Criteria
- Diabetic complications related to heart, eye, nerve problems
- Renal impairment
- Cardiovascular disease
- Hepatic disease
- Prior history of other disorders or complications caused by diseases
- Insulin therapy needed
Data sourced from ClinicalTrials.gov (NCT00690755). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.